Anti-VEGF in Real-world

Diabetic Macular Edema Clinical Trial

Official title: Observation of Anti-vascular Endothelial Growth Factor Therapy in Exudative Age-related Macular Degeneration, Proliferative Diabetic Retinopathy, Macular Edema, and Choroidal Neovascularization.

Status Recruiting

Clinical Trial Summary

Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-vascular endothelial growth factor therapy drugs. In the current study, the primary aim is to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.

Clinical Trial Description

Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases, including neovascular age-related macular edema, diabetic macula edema/non-proliferative diabetic retinopathy / proliferative diabetic retinopathy, retinal vein occlusions related macular edema, and choroidal neovascularization secondary to multiple retinal diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-VEGF drugs. In the current study, the primary aim is to aim to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting. ;

Related Conditions & MeSH terms

• Choroidal Neovascular Membrane
• Diabetic Macular Edema
• Diabetic Retinopathy
• Edema
• Macular Edema
• Non-proliferative Diabetic Retinopathy
• Proliferative Diabetic Retinopathy
• Retinal Diseases
• Retinal Vein Occlusion

• NCT number: NCT05222633
• Study type: Observational
• Source: Beijing Tongren Hospital
• Contact: Wenbin Wei, MD
• Phone: 010-58269523
• Email: weiwenbintr@163.com
• Status: Recruiting
• Start date: January 1, 2022
• Completion date: May 1, 2023